Comparative Pharmacology
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus HALFAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus HALFAN.
CHLOROQUINE PHOSPHATE vs HALFAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Adults: 500 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Category C
Category C
Antimalarial
Antimalarial